French biopharmaceutical firm Transgene has appointed two new executives to its leadership team.
Maud Brandely joins the firm from Pierre Fabre Oncologie, where she most recently served as Director of Clinical Development. John Felitti joins from Sanofi, where he was Associate Vice President, Corporate Law, Finance and Securities Law. Both bring many years of industry and leadership experience to their positions.
In her previous position as Director of Clinical Development at Pierre Fabre Oncologie, Dr Brandely oversaw all clinical trials for the company’s cancer programmes. She played a key role in the successful registration of Navelbine oral (vinorelbine) for the treatment of both breast cancer and non-small cell lung cancer and for vinflunine in transitional cell carcinoma of the urothelial tract.
Prior to this, she was Director of Taxotere Clinical Development at Rhone-Poulenc (now Sanofi), where she was responsible for global registration trials for that product.
At Sanofi, Felitti oversaw legal matters including corporate governance, capital markets, finance, securities litigation and company law. He also headed legal support for a number of major projects, including Sanofi’s successful bid for Genzyme.
Prior to Sanofi, he was an attorney at the international law firm, Shearman & Sterling.
